{"title": "", "body": "See also Metastatic disease alpha-fetoprotein in, 237 alpha-methylacyl-CoA racemase in, 234 225 BG8 in, 225 biopsy in, [208] [209] 207 brain in, 207 Cancer of unknown primary site (CUPS) (Continued) carcinoembryonic antigen in, [222] [223] 206, [907] [908] [909] [910] 237 CD10 in, [235] [236] [231] [232] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] 226 CK1 in, 216t CK5 in, 216t, [218] [219] [218] [219] [212] [213] [214] 217t CK8 in, 216t CK10 in, 216t CK11 in, 216t CK13 in, 216t CK14 in, 216t CK16 in, 216t CK18 in, 216t CK19 in, 212, 216t CK20 in, [214] [215] [216] [217] 216t, 217t, 218t clinical aspects of, [206] [207] [208] 910 combined antibody approach in, 237 cytokeratins in, [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [208] [209] 232 economic considerations in, [206] [207] [208] Cancer of unknown primary site (CUPS) (Continued) thyroid transcription factor-1 in, 227, 228f uroplakin III in, [234] [235] [230] [231] 191 cell-membrane proteins in, 190-192 cutaneous granular cell tumor vs., 199 desmoplastic amelanotic, 190f differential diagnosis of, 197-200 as differential diagnosis of fibrillar mass, 835t epithelial determinants in, 191 in gastrointestinal tract, 526 GP100 in, [193] [194] [195] [191] [192] 194 keratin in, 190f, 190f melanocytic nevus variants vs., 197 metastatic vs. malignant glioma, [198] [199] 195 NB84 in, 192 neuroendocrine markers in, 196 overview of, 189 pigmented actinic keratosis vs., 191 PMel 17 in, [193] [194] [195] [195] [196] Malignant melanoma (MM) (Continued) putatively prognostic markers for, 196-200 rhabdoid, 197 sarcomatoid, 197 sarcomatoid amelanotic, 190f sentinel lymph node biopsies for metastatic, 196 of sinonasal tract, 264-266 small-cell amelanotic, 190f soft-tissue sarcomas vs., 199 tumor-associated glycoprotein-72 in, 191 tyrosinase-related antibodies in, 195 vimentin in, 190f vulvar 164 CD1A in, 164 CD11C in, [164] [165] 161 CD3 in, 162 CD4 in, 162 CD5 in, 162 CD7 in, 162 CD8 in, 162 CD10 in, 164 CD14 in, 165 CD19 in, 165 CD21 in, 158 CD22 in, 158 CD23 in, 158 CD25 in, 158, 165 CD30 in, 165 CD33 in, 165 CD43 in, [165] [166] 166 CD52 in, 166 CD56 in, 167 CD61 in, 167 CD68 in, 167 CD79 in, [158] [159] 167 CD138 in, 159 CD163 Ovarian tumors alpha-fetoprotein in, 723 anti-adenocarcinoma antibodies in, [721] [722] [729] [730] 722 calretinin in, 722 CD45 in, 723 CD117 in, [722] [723] 725 CK7 in, 721, 724, 725, 730 CK20 in, 721, 725 CK125 in, [728] [729] "}